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Abstract
Detection of neuroendocrine neoplasms (NENs) and monitoring of their response to therapy is still challenging due to huge 
heterogeneity of that group of tumors. Actually, NENs visualization is mainly based on molecular imaging while in the past it was 
relied on less effective structural imaging including CT and MRI. Molecular imaging techniques in combination with structural 
imaging (hybrid imaging), especially in patients with well-differentiated NENs, in addition to morphological provide the func-
tional information about tumor which benefits in a more accurate patient management, including more sensitive visualization 
of primary tumors, more precise staging and better therapy follow-up. 
Overexpression of somatostatin receptors (SSTR) on NENs’ cell membrane was a basis for development of somatostatin 
receptor scintigraphy (SRS) using single photon emission tomography SPECT, which is today a well-established standard 
in molecular imaging of NENs, and further imaging improvement in the field of positron emission tomography (PET). Use of 
hybrid imaging (SPECT/CT, PET/CT) increased sensitivity of examination, mainly resulting in better detection of small lesions.
Generally, somatostatin receptor imaging with PET/CT is an emerging technique, although still with limited access, but due to 
several advantages over SSTR SPECT/CT, should be used if available. It is worth mentioning, that both SSTR PET/CT and SSTR 
SPECT/CT have some limitations, such as relatively low detection rate of benign insulinomas, poorly differentiated GEP-NETs 
and liver metastases. For that reason further improvement of NETs imaging is necessary. The most promising new tracers’ 
families are based on SSTR antagonists, 64Cu-radiolabeled ligands and glucagon-like peptide-1 receptor (GLP-1R) imaging. 
Finally, in case of poor-differentiated neuroendocrine cancers 18F-FDG PET/CT may be beneficial in comparison with molecular 
imaging based on somatostatin receptor modalities.
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Introduction
Neuroendocrine neoplasms (NENs) originate from neuroen-
docrine (enterochromaffin) cells located in neuroendocrine tissue 
which are dispersed throughout the body, although are usually 
located in endocrine glands and in gastrointestinal and bronchopul-
monary systems.
Most of NETs are sporadic but about 20% of NENs occur in the 
context of a genetic syndrome like multiple endocrine neoplasia 
types 1 and 2, and von Hippel-Lindau and neurofibromatosis type 1 
and pheohromocytoma/paraganglioma syndromes. 
Neuroendocrine neoplasm group cover GEP-NETs (gastro-
enteropancreatic neuroendocrine tumors) and lung NENs as well 
as other neoplasms originating from a neurocrine cells such 
as pheochromocytoma, paraganglioma, neuroblastoma and 
medullary thyroid cancer [1]. 
NENs are characterized by expression of general neuroendo-
crine tumor markers such as chromogranin A (CgA) and synap-
tophysin. In addition they have an ability to produce peptides, but 
clinically they can be either asymptomatic or symptomatic due 
to excess hormone secretion. It includes functioning carcinoid 
tumors and a variety of other functioning NENs arising mainly from 
the pancreas producing different hormones. Their names reflect 
clinical syndromes such as insulinoma, glucagonoma, gas-
trinoma, VIPoma, although the term carcinoid syndrome is used 
for tumors producing serotonin. The clinical consequences of the 
hormone hypersecretion may be significant (especially in case of 
insulinoma and carcinoid syndrome) but generally total progno-
sis depends, in majority of patients, on the grade and stage of 
the tumor. The last WHO 2010 classification of NENs divides them 
by mitotic or Ki67 index into well differentiated tumors: NET G1 
(MI < 2, Ki-67 ≤ 2%) and NET G2 (MI 3–20, Ki-67 3–20%) and poor 
differentiated cancers: neuroendocrine cancer (NEC) (MI > 20%, Ki-
67 > 20%) and mixed adenoneuroendocrine cancers (MANEC) [2]. 
Recently, there is proposal of a G3 tumors division in accordance 
to their proliferation index into the G3a neuroendocrine tumors with 
Ki-67 20–55% and G3b neuroendocrine cancers (NEC) with Ki-
67 > 50–55%. This suggestion arises from the observation of some 
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differences in biology of G3 NENs. In case of G3a tumors with 
significant SSTR expression seen in SRI (somatostatin receptor 
imagining in SPECT/CT or PET/CT) there is probably a place for 
an attempt of therapy with “cold” somatostatin analogs (SSA) and 
peptide receptor radionuclide therapy (PRRT). In case of G3b can-
cers rather classical oncology management is suggested (Table 1).
The characteristic pattern of NENs is the overexpression of 
specific receptors on their cell surface, which can be visualized by 
molecular imaging techniques.
In this review we summarize the currently available nuclear 
medicine methods of NEN imaging based on visualization of 
somatostatin receptor.
Role of somatostatin receptors  
in molecular imaging
NENs imagining is challenging mainly due to varied place of 
tumors appearance and cellular heterogeneity starting from benign 
lesions up to highly aggressive cancers. In many cases the struc-
tural imaging techniques, like ultrasound, computed tomography 
(CT) or magnetic resonance (MR) have suboptimal diagnostic 
sensitivity making especially diagnosis of the limited disease inef-
fective. Therefore actual guidelines emphasize the importance of 
functional imaging for evaluating the extent of NENs. Molecular 
imaging techniques also in combination with CT or MRI (hybrid 
imaging) in case of well differentiated neoplasm are beneficial in 
comparison with structural imaging especially in localization of 
primary tumors and disease staging. 
Neuroendocrine cells signal to other cells controlling many 
physiological processes by secretion of peptides binding to stimula-
tory or inhibitory receptors on targeted cells. The most important 
among them are somatostatin receptors having in human 5 sub-
types, SSTR1-5, often coexisting in the same cells with different 
expression on normal and cancer cells [3]. 
The distribution of SSTR in NENs differs, depending on the type 
of the tumor and degree of its differentiation. Among them SSTR2 
and SSTR5 are usually overexpressed on NENs cells, while normal 
tissue express mainly SSTR3 and 5.
According to literature, the pancreatic NENs such as gas-
trinomas express SSTR2 in about 100%, SSTR5 in 35%, SSTR3 
in 20% and SSTR1 in 10%, insulinomas express SSTR2 in 70%, 
SSTR1 in 60%, SSTR3 in 35% and SSTR4 in 3% and jejunoileal 
express SSTR2 in about 95%, SSTR1 in 50%, SSTR5 in 48% and 
SSTR3 in 15%, SSTR 4 in 3% [4]. Other currently clinically useful 
receptors in imaging of NEN are glucagon-like peptide-1 receptor 
(GLP-1R) and insulinotropic peptide receptor (GIPR) [3]. 
Naturally occurring somatostatin (SST) is a peptide having 2 
active forms, containing 14 and 28 amino acids, both binding to 
all five subtypes of SSTR. It has a very low metabolic stability in 
vivo (< 2 minutes) forcing development of synthetic somatostatin 
analogues needed for imaging and therapy. By now several types of 
them have been produced, characterized by increased resistance 
to peptidases and having varying affinity to the SSTR subtypes [5] 
(Figures 1, 2). SST analogs affinity profiles for human SSTR are sum-
marized in Table 2. SSTR subtypes expression may be different in the 
primary tumor and in metastases may also change during a treatment 
causing diagnostic confusion and change of patient prognosis. 
Physiological uptake of somatostatin analogs occurs in the 
pituitary, salivary glands, thyroid, liver, spleen, adrenals, pancreas, 
kidneys, ureters, urinary and gall bladder. The greatest confusion 
usually concerns adrenal glands, pancreas and spleen where 
physiological uptake can influence diagnosis of NENs [6] and the 
liver where physiological high uptake of the tracer may influence 
metastases recognition. In addition, it is worth to remember that 
tumors other than NENs including small cell lung cancer, breast and 
ovary cancers, Hodgkin and non-Hodgkin lymphomas, gliomas and 
meningiomas can overexpress SSTR in different pattern [7] caus-
ing that all of them can potentially be visualized by SRI. Moreover, 
Table 1. World Health Organization (WHO) 2010 Classification with modification
Neuroendocrine neoplasm type Grade Ki-67%* Mitotic count (per 10 HPF**)
Neuroendocrine tumor G1 ≤ 2% < 2









Mixed adenoneuroendocrine cancer (MANEC) G1–G3 (mostly G3 component) All ranges All ranges
*Ki-67 index: % of 500–2000 cells in “hot spot areas” stained positive for MIB-1 antibody; **10 HPF: high power field = 2 mm2, based on measurement in at least 50 HPFs in hot spot areas; 
***proposed G3 tumor division in accordance with proliferation index; n/a — non available
Table 2. Somatostatin analog affinity profiles for human SSTRs
Peptides Somatostatin analog SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
SS-28 — 5.2 ± 0.3 2.7 ± 0.3 7.7 ± 0.9 5.6 ± 0.4 4.0 ± 0.3
Octreotide Octreotide > 10.000 2.0 ± 0.7 187 ± 55 > 1.000 22 ± 6
In-DTPA-octreotide In-DTPA-OC > 10.000 22 ± 3.6 182 ± 13 > 1.000 237 ± 52
DOTA-(Tyr3)-octreotate DOTA-TATE > 10.000 1.5 ± 0.4 >1.000 453 ± 176 547 ± 160
Ga-DOTA-(Tyr3)-octreotate Ga-DOTA-TATE > 10.000 0.2 ± 0.04 >1.000 300 ± 140 377 ± 18
Ga-DOTA-(Tyr3)-octreotide Ga-DOTA-TOC > 10.000 2.5 ± 0.5 613 ± 140 > 1.000 73 ± 21
Ga-DOTA-l-Nal3-octreotide Ga-DOTA-NOC > 10.000 1.9± 0.4 40 ± 5.8 260 ± 74 7.2 ± 1.6
DOTA-lanreotide DOTALAN >10.000 26 ± 3.4 771 ± 229 >10.000 73 ± 12
All values are IC50 ± SEM in nmol/l
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some somatostatin analogs accumulation may occur in benign 
lesions like respiratory tract infection, probably due to local lym-
phocytes activation, in the infection of joints including rheumatoid 
arthritis, Wegener’s granuloma, tuberculosis, sarcoidosis, in healing 
scars, aeries underwent radiotherapy [8] or due to osteoclastic 
activity in degenerative bone diseases, fractures, fibrous dysplasia 
or vertebral hemangioma [6]. 
Somatostatin analogs in molecular imaging 
The role of molecular imaging in diagnosis, staging and follow-up 
of NETs increases with concomitant development of hybrid imaging 
and new tracers’ synthesis including use of positron emitters. 
First radiopharmaceutical used in SRS was 111In-diethylenetri-
aminepentaacetic acid-D-Phe1-octreotide (111In-DTPA-octreotide) 
which became an integral part of the management of patients with 
NENs. Later, alternative somatostatin receptor agonists, labeled with 
the 99mTc obtained from 99Mo/99mTc radionuclide generators were 
available and were extensively used in the clinical practice, such as 
99mTc-EDDA-hydrazinonicotinyl-Tyr3-octreotate (99mTc-HYNIC-TATE) 
[9] and 99mTc-EDDA-hydrazinonicotinyl-Tyr3-octreotide (99mTc-EDDA/ 
/HYNIC-TOC) [10]. Both of these tracers seem to have similar 
NENs sensitivity [11]. Use of 99mTc instead of 111In has lots of 
advantages like lower costs of examination, earlier image acquisi-
tion and wider availability with most studies comparable or higher 
sensitivities to 111In-DTPA-octreotide [12, 13]. 
Figure 1. 77 year-old-women with liver NEN (NET G2 according to WHO 2010 classification). A. 99mTc-HYNIC-TOC SPECT/CT of abdomen; B. 
follow-up 68Ga-DOTA-TATE PET/CT. True or false NEN progression? Are all of the extra “hot spots” a sign of the disease progression or are only the 
effects of use of different SSA or more sensitive method of visualization?
A B
Figure 2. 99mTc-HYNIC-TATE scintigraphy. A. 46-year-old women with bronchial NEN having expression of only SSTR 3 (obtained in 
histopathology); B. 56-year-old man with duodenal NEN having expression of all subtypes of SSTR (obtained in histopathology: high 2A, good 1, 
2B, moderate 3, 5)
A B
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The next generation of labeled SSA are tracers for PET. Currently 
three major, clinically useful, tracers for PET/CT imaging radiolabeled 
with 68Ge/68Ga radionuclide generator obtained 68Ga are available: 
68Ga-DOTA-Phe1-Tyr3-Octreotide (DOTATOC), 68Ga-DOTA-NaI3-Oc-
treotide (DOTANOC), and 68Ga-DOTA-Tyr3-Octreotate (DOTATATE) 
[10]. These tracers present some differences in pharmacokinet-
ics but more importantly, their affinity to SSTR subtypes varies [8]. 
All of them can bind to SSTR2 while 68Ga-DOTANOC also has affinity 
for SSTR 3 and 5 and 68Ga-DOTATOC for SSTR 5 [14].
Clinical utility of SSTR imaging
Methods of SSTR visualization have well established posi-
tion in NENs imaging. Its utility is especially connected with 
GEP-NETs and lung carcinoid visualization. The majority of these 
tumors express high number of SSTRs, present on both primary 
and metastatic sites [1]. In that cases SSTR imaging facilitates pa-
tients management including staging, detection of new sites of 
disease in patients with treated NETs (restaging), diagnosis of 
patients with suspicion of NEN based on biochemical or clinical find-
ings, localization of primary tumor in case of initially disseminated 
disease, selection of candidates for cold SSA or peptide receptor 
radionuclide therapy PRRT [15]. Finally, those methods are useful 
in monitoring of response to the therapy. In patients with metastatic 
or inoperable NENs that have little or no uptake of radiolabeled 
SSA, the likelihood of response to long-acting SSA is significantly 
reduced and these patients are also unsuitable for PRRT. 
Sensitivity of different imaging modalities varies for specific 
NENs. SRS specificity for detection of primary GEP-NETs is 86–95% 
and is higher than for location of pancreatic gastrin/VIP/somatosta-
tin-secreting NETs (75%) and insulinomas (50–60%) [16]. In vari-
ous studies sensitivity of 68Ga-DOTA-peptides in PET/CT detection 
of NETs has been proven higher than for SRS [17–19]. For primary 
NENs its sensitivity is estimated at 78–93% and is highest for pancre-
atic NENs (86–100%) except insulinomas in which case the sensitiv-
ity is in general lower starting from 25% in case of 68Ga-DOTANOC 
[20] up to 87% in case of DOTATOC [21]. Similar effectiveness for 
68Ga-DOTA-peptides was established in PET/CT in patients with 
clinical/biochemical/radiological suspicion of NENs [22]. 
Among gastric NENs the somatostatin receptor imaging can be 
useful in type 2 and 3 of NENs as a part of the overall staging and 
may facilitate choosing of therapy. Somatostatin receptor imaging 
is seldom useful for type 1 gastric NENs which are usually indolent 
and require mainly gastroscopic supervision [23].
According to literature, SRI in combination with CT may be 
considered in patients with appendix NEN, while resection of NEN 
is considered as not complete or when distant metastatic disease 
is suspected [24].
For jejunum and ileum, NENs SRI has sensitivities of approxi-
mately 90% for primary tumors with or without nodal involvement 
and > 95% for liver metastases. That indicate SRI as an important 
tool for staging and follow-up in patients with jejunum and ileum 
NENs [25]. For that group of NENs 68Ga-DOTA-peptides PET/CT 
was confirmed to be more useful in comparison with 111In-DTPA oc-
treotide SPECT/CT in searching for a primary tumor in patients with 
unknown or suspected disease.
Due to the high sensitivity of SRI in detection of pancreatic 
NENs, especially in PET/CT techniques, use of 68Ga-DOTA-pep-
tides is now the method of choice to fully stage and localize the ex-
tent of disease in patients with non-insulinoma pancreatic NETs [26]. 
In case of colorectal NENs, tumor size and its depth predict node 
metastasis. Intramucosal tumors < 1 cm have a 4% risk of lymph node 
metastasis. Although the risk of metastasis of colorectal NENs is not 
zero even for small tumors, the majority of patients appear cured 
once full resections of small (< 10 mm) rectal NENs with favorable 
biology is done. In case of tumors > 2 cm the risk of metastatic 
disease is 60%. For that reasons ENETs recommend SRI, as one of 
visualization possibility, in patients with tumors > 2 cm and grade 
1 and 2 or tumors > 1cm grade 3 or suspicion of metastasis [27]. 
Lung NENs express SSTR1 and SSTR2 in 70% and SSTR5 in 
20% [28]. According to literature for typical bronchial carcinoids SRI, 
especially in PET/CT techniques is a sensitive tool of its visualization 
and has in general higher sensitivity than for atypical ones [5, 29]. 
Generally, well-differentiated tumors are detected in SRI with 
higher sensitivity than high-grade tumors which are usually seen 
in 18F-FDG PET/CT. However somatostatin receptor scintigraphy 
is not routinely indicated in G3 tumors, but may be considered 
in tumors with proliferative indexes in the low range of G3 (Ki-
67 < 55%) [30]. 
In case of metastatic disease from NENs, the metastases are 
predominantly found in the liver, lymph nodes and/or bones chang-
ing grading of the disease. Use in comparable clinical trials more 
sensitive imaging methods such as 68Ga-DOTA peptides PET/CT 
shows that real number of metastases especially in bones is higher 
than estimated by conventional radiological techniques [31].
According to literature, 68Ga-DOTA-peptides have been 
shown to change the management (surgical, medical, staging) 
in comparison with structural imagining (CT, MRI) and even with 
SRS. The diagnostic accuracy of SSTR PET/CT in patients with 
known NEN is higher than CT or MRI [32]. PET/CT results change 
clinical management in 38%–60% of the examined patients. In 
patients with negative or equivocal 111In-DTPA-octreotide findings, 
68Ga-DOTATATE PET identified significantly more lesions than 
111In-DTPA-octreotide scintigraphy [17]. Simultaneously done 
SRS with 99mTc-HYNIC-TOC or 111In-DOTA-TOC and compared 
with 68Ga-DOTA-TOC PET showed higher sensitivity of PET/CT 
which provided additional valuable clinical information in 14.3% 
of investigated patients, mainly reviling non-seen in SRS bone 
metastases [18]. The consequence of above findings cause 
68Ga-DOTA-peptides PET/CT should be the method of choice in 
management of well differentiated NENs (especially GEP-NETs tu-
mors excluding patient with suspicion of insulinoma) [15]. 
The high expression of SSTR enables also SRI imaging of other 
neuroendocrine tumors being in some cases useful in staging, 
restaging and follow-up of pheochromocytomas, paragangliomas, 
neuroblastomas or medulloblastomas [28]. 
Insulinoma visualization
Due to relatively low sensitivity of SRI, especially in case of 
benign, insulinomas there is a need for new tracer synthesis dedi-
cated for insulinoma detection. Strong overexpression of glucagon-
like peptide-1 (GLP-1) receptors in human insulinoma provides it 
as an attractive target for imaging.
By now, clinical trials have demonstrated usefulness of 
GLP-1 receptor in SPECT/CT imagining using (Lys40(Ahx (6-ami-
Nuclear Medicine Review 2016, Vol. 19, No. 2
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nohexanoic acid)-DOTA-111In)NH2)-exendin-4 as well as causing rel-
atively lower radiation burden for the patient (Lys40(Ahx-DOTA-68Ga)
NH2)-exendin-4 for PET/CT and (Lys
40(Ahx-hydrazinonicotinamide 
(HYNIC)-99mTc)NH2)-exendin-4 for SPECT/CT [27, 34] (Figure 3).
Somatostatin receptor imaging in SPECT/CT 
SRS in SPECT/CT technique has well established position in 
management of NENs patients. After development of tracers based 
on generator obtained 99mTc, confirmation of its diagnostic sensitivity 
and favorable dosimetry [35] caused that value and availability of 
SRS for localization of primary tumor, staging, follow-up and quali-
fication to PRRT significantly increased. Currently, for commercial 
use 99mTc-EDDA/HYNIC-TOC (Tektrotyd, Poland) is available in 19 
European countries and is indicated for use in adults for indication 
mention above. Relatively low cost of that tracers and its wide acces-
sibility cause that SRS is still a very useful tool in NEN patients man-
agement especially in areas with limited access to PET/CT scanners. 
Somatostatin receptor imaging in PET/CT
Since PET/CT scanners are relatively easy available there 
is a trend to shift NENs diagnostic from conventional SRS to PET/CT 
mainly because of their multifocal superiority in comparison with 
gamma-emitters. In case of PET/CT examination spatial resolu-
tion is much higher toward SPECT (3–6 mm versus 10–15 mm), 
which provides mainly better visualization of small lesions. PET/CT 
save time because at once it is possible to scan all body not only 
a one region. Moreover there is commercially available genera-
tor (68Ge/68Ga) so there is no need of cyclotron use and PET/CT 
may be available in any Nuclear Medicine Unit. The long life of 
the mother radionuclide 68Ge (270.8 days) allows for generator 
use even 12 months and the elution can be done even every 
3 hours. As for as SRS discontinuation of long acting somatosta-
tin analog before examination is recommended, although is not 
mandatory. This has clinical implication that a wide spectrum of 
ligands (68Ga-DOTA-peptides) should be invited for NENs imaging. 
Some authors suggest that 68Ga-DOTANOC is more sensitive than 
SSTR2 specific 68Ga-DOTATATE [36]. However, there is currently no 
evidence of a clinical impact of these differences in SSTR binding 
affinity, and therefore no preferential use of one compound over 
the others is recommended [6]. 
18F-FDG PET/CT in NENs imagining
For a well-differentiated NENs PET scanning with the use of 
18F-FDG is not recommended due to low sensitivity for G1 and 
in many cases G2 tumors (95%sensitivity of 68Ga-DOTATATE 
for GEP-NETs grade G1 and 2 versus 37% in case of 18F-FDG) 
[37] (Figure 4). In the group of patients with the Ki-67 > 15% the 
18F-FDG PET/CT uptake was find in over 90% patients [38]. In all 
patients 18F-FDG PET/CT may provide complementary information 
Figure 3. 62-year-old women with MEN1 syndrome with suspicion of insulinoma recurrence due to clinical symptoms. A. Negative result of 99mTc-
HYNIC-TOC scintigraphy; B. clearly visible in 99mTc-GLP-1 scintigraphy pancreatic tumor
A B
A B
Figure 4. Comparison of high uptake of 68Ga-DOTATATE (A) in the rectum and metastases to pubic bone with moderate uptake of 18F-FDG (B) in 
PET/CT in 56-year-old men with metastatic NEN (NET G2 according to WHO 2010 classification) done to localization of primary tumor
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to SSTR imaging having prognostic value. Loss of SSTR recep-
tors by NENs is usually connected with higher percentage of 
cells demonstrating the proliferation marker Ki-67, higher 18F-FDG 
uptake and poorer prognosis. Additionally, 18F-FDG PET may be 
considered in patients in whom radical surgery is being pursued or 
if clarification of equivocal findings on conventional imaging may 
change the therapeutic approach [30]. 
Some initial studies suggest correlation between 68Ga-DOTA 
-TATE or 18F-FDG uptake and tumor grade on histology. Since the 
most aggressive NENs are often non seen in SSTR imaging and 
usually seen in 18F-FDG PET, there is probably diagnostic future for 
staging patients with NENs who are negative in SSTR imaging [39].
Other NENs specific tracers
In last few years 18F-DOPA (dihydroxyphenylalanine) has ap-
peared. As a precursor of neurotransmitters, DOPA is taken up by 
some of neuroendocrine cells. In initial studies comparing 18F-DOPA 
with 68Ga-DOTA-peptides, higher sensitivity of 68Galabeled trac-
ers than 18F-DOPA in GEP-NET localization was shown [40] 
as well as in detection of well-differentiated metastatic NENs [41]. 
Moreover, 68Ga-DOTANOC was more sensitive to 18F-DOPA and 
123I-MIBG [42] in case of tumors which should prefer amine precur-
sor uptake, like pheochromocytoma, paraganglioma or medullary 
thyroid cancer. 
Observation of a correlation between SUV max of 18F-DOPA 
and serotonin plasma serum level may suggest some usefulness of 
this tracer in detection of tumors secreting serotonin, not visual-
ized by SRI [43]. Gluc-Lys 18F-FP-TOCA is another SSTR targeted 
radiopharmaceutical with initial results suggesting comparable sen-
sitivity and specificity of 68Ga-DOTATATE in detection of NENs [44]. 
11 C-5-HTP (hydroxytryptophan) have shown promising results in 
detection of NENs, but further studies are necessary to confirm 
its utility [45]. Medullary thyroid cancer has an ability to take up 
gastrin and CCK-2 analogs which can be potential tools for diag-
nostic approach in that malignancy [46, 47].
Future perspectives
The role of SSTR imaging with radiolabeled somatostatin 
analogs is well established in clinic, but there is still a lot of un-
certainty which needs elucidation, including selecting of the most 
sensitive peptides for NENs or their subgroups imagining. Use of 
different radionuclides and radiolabeling strategies influences pep-
tide’s SSTR affinity and changes radiopharmaceutical properties. 
By now, 18F-SSTR tracers were synthesized but they did not suc-
ceed as much as tracers radiolabeled with for example 64Cu, such 
as 64Cu-DOTATATE [48] or 64Cu-TETATOC [49]. It is expected that 
tracers based on 64Cu provide images with better resolution, higher 
sensitivity and will have favorable dosimetry allowing their therapeu-
tic use. In the quest for ligands with a wider receptor affinity profile 
the 177Lu/68Ga-DOTA-AM3 has been developed which is a new 
bicyclic somatostatin-based radiopeptide with high affinity for all 
5 subtypes of SSTR. The pharmacokinetic data make this peptide 
an excellent candidate as an imaging radiotracer [50]. Finally, 
investigation of other specific tracers as GLP-1R analogs for insu-
linomas or CCK-2 analogs for MTC may aid in NENs visualization.
The first in vitro study suggests that the use of a cocktail of 3 ra-
dioligands binding to somatostatin receptors, GLP-1 receptors, and 
GIP receptors would allow detecting virtually all NETs and labeling 
them homogeneously in vivo, representing a significant improve-
ment for imaging and therapy in NETs [51]. Furthermore, using of 
somatostatin receptor antagonist, such as 111In-DOTA-BASS [52] or 
68Ga-NODAGA-JR11 [53], may in future improve diagnostic value 
of SRI techniques.
Conclusion
Conventional radiological imaging modalities, including ul-
trasound, CT, MRI and EUS, are important tools in NEN patients’ 
management, but in many cases especially in well-differentiated 
tumors are not always sufficient enough for the detection of the 
primary tumor, staging and evaluation of treatment response. 
Molecular imaging techniques, especially with the use of SSA, 
increase sensitivity of NENs imaging. Introduction to NENs diag-
nostic hybrid imaging modalities and tracers based on SSA had 
a noticeable impact in NENs patient management. The develop-
ments in SRS followed by the progress in the design of PET tra-
cers additionally facilitated localization of primary tumors, improved 
staging, restaging and follow-up. 
It should be emphasized that using of SSTR SPECT/CT is still 
a valuable imaging method of NENs especially in case of limited 
access to PET/CT scanners.
18F-FDG PET/CT is not recommended as first-line diagnostic 
option for well-differentiated NENs imaging but in some cases may 
deliver complementary information to SRI especially in case of more 
aggressive tumors influencing clinical management and having 
prognostic value. In insulinomas, especially in benign ones, due to 
low sensitivity of SRI, the use of GLP-1R analogs may be considered.
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